Biotechnology · Grasonville, Maryland, United States
$1.67
+11.36% (+$0.17)2026-07-09
Net Income-$10.4M
EPS$-0.27
Market Cap$65.6M
Price Performance
Historical data including institutional events
Company Profile
P
Paul Romness
CEO & Executive Director
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
